Research ArticleDrug Discovery and Translational Medicine
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Melissa Hopper, Tarikere Gururaja, Taisei Kinoshita, James P Dean, Ronald J Hill and Ann Mongan
Journal of Pharmacology and Experimental Therapeutics December 23, 2019, jpet.119.262063; DOI: https://doi.org/10.1124/jpet.119.262063
Melissa Hopper
Pharmacyclics LLC, an AbbVie Company
Tarikere Gururaja
Pharmacyclics LLC, an AbbVie Company
Taisei Kinoshita
Pharmacyclics LLC, an AbbVie Company
James P Dean
Pharmacyclics LLC, an AbbVie Company
Ronald J Hill
Pharmacyclics LLC, an AbbVie Company
Ann Mongan
Pharmacyclics LLC, an AbbVie Company
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Melissa Hopper, Tarikere Gururaja, Taisei Kinoshita, James P Dean, Ronald J Hill and Ann Mongan
Journal of Pharmacology and Experimental Therapeutics December 23, 2019, jpet.119.262063; DOI: https://doi.org/10.1124/jpet.119.262063
Research ArticleDrug Discovery and Translational Medicine
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Melissa Hopper, Tarikere Gururaja, Taisei Kinoshita, James P Dean, Ronald J Hill and Ann Mongan
Journal of Pharmacology and Experimental Therapeutics December 23, 2019, jpet.119.262063; DOI: https://doi.org/10.1124/jpet.119.262063
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement